Information about Molindone
Molindone is a conventional antipsychotic used in the therapy of schizophrenia.
Liver safety of Molindone
Molindone therapy is commonly associated with minor serum aminotransferase elevations but has rarely been linked to cases of clinically apparent acute liver injury.
Mechanism of action of Molindone
Molindone (moe lin' done) is a dihydroindolone antipsychotic medication that is not structurally related to the phenothiazines and which appears to act by blocking dopamine type 2 (D2) receptors. Molindone has other central and peripheral effects including anticholinergic and alpha adrenergic blockade.
FDA approval information for Molindone
Molindone was approved for use in the therapy of psychotic disorders in the United States in 1974. Since then, however, molindone has been replaced in large part by the atypical antipsychotics, which have fewer extrapyramidal side effects.
The drug Molindone was withdrawn from the US market
Molidone was withdrawn from use in the United States in 2013, but was previously available as tablets of 5, 10, 25 and 50 mg generically and under the brand name Moban. Recommended doses of molindone were 50 to 75 mg daily initially, increasing based upon efficacy and tolerance to as high as 225 mg daily.
Side effects of Molindone
Second Generation (Atypicals)
- Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Pimavanserin, Quetiapine, Risperidone, Ziprasidone